Drugs / SEPO®
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05301517 Comparator | Mar 2022 → Apr 2023 | aregenerative anemia | Kyntra Bio | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SEPO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05301517 ↗ |
| Modality | Protein / enzyme biologic | “subcutaneous recombinant human erythropoietin-α (rHuEPO-α) three times a week for 12 weeks” PMID 39353163 ↗ Oct 2024 |
| Route | Subcutaneous | “Participants will receive SEPO®, injected subcutaneously TIW for 12 weeks” NCT05301517 ↗ |